Recent Updates
Recently added Catalysts
FOLD

Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium

Key Takeaway: PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium, being held Septemb

Full Press Release Details

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium, being held September 3-6, 2024 in Porto, Portugal.
Abstract Title: FollowME Fabry Pathfinders registry: patient-reported outcomes in a cohort of patients on migalastat treatment for at least two years (Poster #21180)
Presenter: Aleš Linhart, D.Sc., Charles University and General University Hospital in Prague, Prague, Czech Republic
Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
Location: Poster Room, Rosa Mota Pavilion
Abstract Title: Quality of life of migalastat-treated adolescents with Fabry disease: results from the ASPIRE study and open-label extension (Poster #21202)
Presenter: Amarilis Sanchez-Valle, MD, University of South Florida Health, Tampa, U.S.A.
Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
Location: Poster Room, Rosa Mota Pavilion
Abstract Title: Exploring the journey of patients living with Fabry disease in Poland (Poster #20789)
Presenter: Anna Moskal, The Association of Families with Fabry Disease, Wroclaw, Poland
Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
Location: Poster Room, Rosa Mota Pavilion
Abstract Title: Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease (Poster #20863)
Presenter: Elaine Murphy, MD, University College London Hospitals, London, U.K.
Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
Guided Poster Walk: Thursday, September 5, 12:10 – 1:40 p.m. WET
Location: Poster Room, Rosa Mota Pavilion
Abstract Title: Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease (Poster #20873)
Presenter: Mark Roberts, MD, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, Manchester, U.K.
Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
Location: Poster Room, Rosa Mota Pavilion
For more information on the SSIEM 2024 Annual Symposium, please visit ssiem2024.org.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.
Vice President, Investor Relations
Head of Global Corporate Communications
Last updated: Sep 3, 2024